The Neuroendocrine Tumor Research Foundation announced its latest Request for Applications and invites innovative research applications in neuroendocrine tumors that can bring the field closer to more effective therapies.
This uncommon cancer occurring in hormone-producing cells is often overlooked for research funding. NETRF serves as the major private funder of NET cancer research.
To ensure that high-quality, meaningful research proposals are selected, NETRF uses a rigorous peer review process, which includes external expert reviewers and a Board of Scientific Advisors.
Interested applicants must submit a letter of intent by June 13. From that pool, exceptional investigators with the most promising and transformative ideas will be invited to submit full proposals. Grant awards will be announced in December 2018.
Last year NETRF invested heavily in a targeted form of radiation called peptide receptor radionuclide therapy.
Since 2005, NETRF has funded $20 million in scientific research grants to expand the molecular understanding of NETs and help drive personalized treatment options for patients. NET research projects have been funded in the U.S., Canada, United Kingdom, Switzerland, Australia, and the Netherlands.
